Adam S. Asch

6.3k total citations · 1 hit paper
98 papers, 4.6k citations indexed

About

Adam S. Asch is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Adam S. Asch has authored 98 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 30 papers in Oncology and 24 papers in Hematology. Recurrent topics in Adam S. Asch's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (15 papers) and Platelet Disorders and Treatments (11 papers). Adam S. Asch is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (15 papers) and Platelet Disorders and Treatments (11 papers). Adam S. Asch collaborates with scholars based in United States, United Kingdom and Switzerland. Adam S. Asch's co-authors include Ralph L. Nachman, Roy L. Silverstein, J W Barnwell, Ethel Cesarman, Leandros Arvanitakis, Enrique A. Mesri, Chinthalapally V. Rao, John W. Barnwell, Omar A. Coso and Hiroshi Yamada and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Adam S. Asch

91 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator

1998 677 citations Carlos Bais, Bianca Santomasso et al. Nature profile →

Peers

Countries citing papers authored by Adam S. Asch

Since Specialization

Citations

This map shows the geographic impact of Adam S. Asch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam S. Asch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam S. Asch more than expected).

Fields of papers citing papers by Adam S. Asch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam S. Asch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam S. Asch. The network helps show where Adam S. Asch may publish in the future.

Co-authorship network of co-authors of Adam S. Asch

This figure shows the co-authorship network connecting the top 25 collaborators of Adam S. Asch. A scholar is included among the top collaborators of Adam S. Asch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam S. Asch. Adam S. Asch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma 2024 ·Blood Advances ·(unknown), Adam S. Asch, Leslie Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colm Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Gal Hacohen-Kleiman, (unknown), (unknown), (unknown), Sonali M. Smith, Ranjana H. Advani	6
2	Abstract 506: TRIP13 is a promising therapeutic target for bladder cancer 2024 ·Cancer Research ·Surya Pratap Singh, (unknown), Adam S. Asch, Chinthalapally V. Rao, Venkateshwar Madka	0
3	Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease 2024 ·Blood ·Miloš D. Miljković, Adam S. Asch, Gregory Orloff, Ralph V. Boccia, Jesús G. Berdeja, Fevzi Altuntaş, Stefan O. Ciurea, James F. Howard, Tuan Vu, Bennett Myers, Nizar Chahin, Tahseen Mozaffar, Christopher M. Jewell, Metin Kurtoğlu	1
4	Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer. 2023 ·Journal of Clinical Oncology ·David H. Aggen, David S. Hong, Jeffrey Clarke, Adam S. Asch, Emiliano Calvo, Jon Zugazagoitia, Marcus O. Butler, Víctor Moreno, Andrés Cervantes, Brian Andrew Van Tine, Donald P. Lawrence, Melissa L. Johnson, (unknown), (unknown), (unknown), (unknown), Jean‐Marc Navenot, (unknown), Elliot Norry, John A. Charlson	1
5	Bladder Cancer Prevention: Potential Molecular Targets and Their Clinically Relevant Agents 2023 ·Current Pharmacology Reports ·Surya P. Singh, Adam S. Asch, Chinthalapally V. Rao, Venkateshwar Madka	1
6	An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth 2023 ·Molecular Therapy — Nucleic Acids ·(unknown), Constantin Georgescu, Lin Wang, Jonathan D. Wren, Magdalena Bieniasz, Chao Xu, Adam S. Asch, (unknown)	1
7	Genomic instability genes in lung and colon adenocarcinoma indicate organ specificity of transcriptomic impact on Copy Number Alterations 2022 ·Scientific Reports ·Chinthalapally V. Rao, Chao Xu, Yuting Zhang, Adam S. Asch, Hiroshi Yamada	4
8	Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells 2021 ·Molecular Therapy — Nucleic Acids ·(unknown), Constantin Georgescu, Jonathan D. Wren, Chao Xu, Adam S. Asch, Maria J. Ruiz‐Echevarría	7
9	Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model 2019 ·Cancer Prevention Research ·Venkateshwar Madka, Gaurav Kumar, Gopal Pathuri, Yuting Zhang, Stanley Lightfoot, Adam S. Asch, Altaf Mohammed, Vernon E. Steele, Chinthalapally V. Rao	9
10	Emerging links among Chromosome Instability (CIN), cancer, and aging 2016 ·Molecular Carcinogenesis ·Chinthalapally V. Rao, Adam S. Asch, Hiroshi Yamada	21
11	The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells 2014 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Xiaofei Chen, (unknown), (unknown), Li V. Yang, Adam S. Asch, Maria J. Ruiz‐Echevarría	12
12	Androgen Signaling Promotes Translation of TMEFF2 in Prostate Cancer Cells via Phosphorylation of the α Subunit of the Translation Initiation Factor 2 2013 ·PLoS ONE ·(unknown), Vesna A. Chappell, (unknown), Christopher B. Geyer, Adam S. Asch, Maria J. Ruiz‐Echevarría	18
13	Activation of GPR4 by Acidosis Increases Endothelial Cell Adhesion through the cAMP/Epac Pathway 2011 ·PLoS ONE ·Aishe Chen, Lixue Dong, Nancy R. Leffler, Adam S. Asch, Owen N. Witte, Li V. Yang	115
14	Role of benzo[α]pyrene in generation of clustered DNA damage in human breast tissue 2010 ·Free Radical Biology and Medicine ·George Sigounas, (unknown), (unknown), (unknown), Adam S. Asch, Douglas A. Weidner, John E. Wiley	15
15	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator 1998 ·Nature ·Carlos Bais, Bianca Santomasso, Omar A. Coso, Leandros Arvanitakis, (unknown), J. Silvio Gutkind, Adam S. Asch, Ethel Cesarman, Marvin C. Gershengorn, Enrique A. Mesri	27
16	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator breakdown → 1998 ·Nature ·Carlos Bais, Bianca Santomasso, Omar A. Coso, Leandros Arvanitakis, (unknown), J. Silvio Gutkind, Adam S. Asch, Ethel Cesarman, (unknown), Enrique A. Mesri	677
17	Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. 1996 ·The Journal of Experimental Medicine ·Enrique A. Mesri, Ethel Cesarman, Leandros Arvanitakis, Shahin Rafii, Malcolm A.S. Moore, David N. Posnett, Dan Knowles, Adam S. Asch	194
18	Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices 1995 ·The Annals of Thoracic Surgery ·Shahin Rafii, Mehmet C. Öz, J. Alex Seldomridge, Barbara Ferris, Adam S. Asch, (unknown), Fred Shapiro, Eric A. Rose, Howard R. Levin	85
19	A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. 1989 ·Journal of Clinical Investigation ·John W. Barnwell, Adam S. Asch, Ralph L. Nachman, M. Yamaya, Masanori Aikawa, Paul Ingravallo	314
20	Identification and isolation of a platelet GPIb-like protein in human umbilical vein endothelial cells and bovine aortic smooth muscle cells. 1988 ·Journal of Clinical Investigation ·Adam S. Asch, Burt Adelman, (unknown), Ralph L. Nachman	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact